Primers and probes for detection and discrimination of types and subtypes of influenza viruses
Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.
1. A probe and primer set comprising:
a probe for detecting an influenza B virus nucleic acid, wherein the probe consists of the nucleotide sequence set forth as SEQ ID NO: 29 and at least one attached label, wherein the at least one attached label is a radioactive isotope, enzyme substrate, co-factor, ligand, chemiluminescent agent, fluorophore, hapten, enzyme, chemical, or combination thereof; and
primers consisting of a nucleic acid sequence set forth as SEQ ID NO: 26 and a nucleic acid sequence set forth as SEQ ID NO: 28, or primers consisting of a nucleic acid sequence set forth as SEQ ID NO: 27 and a nucleic acid sequence set forth as SEQ ID NO: 28.
2. The probe and primer set of claim 1 , wherein the probe is labeled with a fluorophore.
3. The probe and primer set of claim 2 , wherein the probe is further labeled with a fluorescence quencher.
4. The probe and primer set of claim 1 , wherein the probe is labeled with biotin.
5. A method for diagnosing an influenza virus infection in a subject suspected of having an influenza infection, comprising:
contacting a sample comprising nucleic acid molecules obtained from the subject with the probe and primer set of claim 1 ;
amplifying influenza virus nucleic acid molecules in the sample with the primers, thereby generating amplified influenza virus nucleic acid molecules;
detecting hybridization between the amplified influenza virus nucleic acid molecules and the probe; and
determining that the subject is infected with influenza virus when hybridization between the amplified influenza virus nucleic acid molecules and the probe is detected.
6. The method of claim 5 , wherein detecting hybridization between the amplified influenza virus nucleic acid molecules and the probe indicates the presence of influenza type B in the sample.
7. The method of claim 5 , wherein the probe is labeled with a fluorophore.
8. The method of claim 7 , wherein the probe is further labeled with a fluorescence quencher.
9. The method of claim 5 , wherein detecting hybridization comprises detecting a change in signal from a label attached to the probe during or after hybridization relative to signal from the label before hybridization.
10. The method of claim 5 , wherein the amplifying comprises polymerase chain reaction (PCR), real-time PCR, reverse transcriptase-polymerase chain reaction (RT-PCR), real-time reverse transcriptase-polymerase chain reaction (rt RT-PCR), ligase chain reaction, or transcription-mediated amplification (TMA).
11. The method according to claim 5 , wherein the sample is obtained from bronchoalveolar lavage, tracheal aspirates, sputum, nasopharyngeal aspirates, oropharyngeal aspirates, or saliva.
12. The method of claim 5 , wherein the probe is arrayed in a predetermined array with an addressable location.
13. A method for detecting influenza virus nucleic acid molecules in a sample, comprising:
contacting the sample with the probe and primer set of claim 1 ;
amplifying influenza virus nucleic acid molecules in the sample with the primers, thereby generating amplified influenza virus nucleic acid molecules;
detecting hybridization between the amplified influenza virus nucleic acid molecules and the probe; and
determining that the influenza virus nucleic acid molecules are present in the sample when hybridization between the amplified influenza virus nucleic acid molecules and the probe is detected.
14. The method of claim 13 , wherein detecting hybridization between the amplified influenza virus nucleic acid molecules and the probe indicates the presence of influenza type B in the sample.
15. The method of claim 13 , wherein the probe is labeled with a fluorophore.
16. The method of claim 15 , wherein the probe is further labeled with a fluorescence quencher.
17. The method of claim 13 , wherein detecting hybridization comprises detecting a change in signal from a label attached to the probe during or after hybridization relative to signal from the label before hybridization.
18. The method of claim 13 , wherein the amplifying comprises polymerase chain reaction (PCR), real-time PCR, reverse transcriptase-polymerase chain reaction (RT-PCR), real-time reverse transcriptase-polymerase chain reaction (rt RT-PCR), ligase chain reaction, or transcription-mediated amplification (TMA).
19. The method according to claim 13 , wherein the sample is a biological sample obtained from a subject.
20. The method of claim 19 , wherein the presence of influenza virus nucleic acid molecules in the biological sample indicates the presence of an influenza virus infection in the biological sample obtained from the subject.
21. The method according to claim 20 , wherein the biological sample is obtained from bronchoalveolar lavage, tracheal aspirates, sputum, nasopharyngeal aspirates, oropharyngeal aspirates, or saliva.
22. The method of claim 13 , wherein the probe is arrayed in a predetermined array with an addressable location.
23. The probe and primer set of claim 1 , wherein the probe comprises a fluorophore on its 5′-end and a fluorescence quencher on its 3′-end.
24. A kit for detecting an influenza virus nucleic acid molecule in a sample, comprising:
a probe for detecting an influenza B virus nucleic acid, wherein the probe consists of the nucleotide sequence set forth as SEQ ID NO: 29 and at least one attached label, wherein the at least one attached label is a radioactive isotope, enzyme substrate, co-factor, ligand, chemiluminescent agent, fluorophore, hapten, enzyme, chemical, or combination thereof; and
a pair of primers consisting of the nucleic acid sequences shown in SEQ ID NO: 26 and SEQ ID NO: 28 or a pair of primers consisting of the nucleic acid sequences shown in SEQ ID NO: 27 and SEQ ID NO: 28.
25. The kit of claim 24 , wherein the kit comprises an array that comprises the probe, or a device comprising an array that comprises the probe.
26. The kit of claim 24 , wherein the kit further comprises a human RNAse P control probe.